Cure My Disease

Don't miss your cure!

 Log in / Sign up

Real-World data shows MS Drug's impact on relapses and daily life

NCT ID NCT06251986

Completed Disease control Sponsor: Novartis Pharmaceuticals Source: ClinicalTrials.gov ↗

Summary

This study looked at how well the multiple sclerosis (MS) treatment ofatumumab (brand name Kesimpta) worked for people in everyday Spanish clinics, not just in controlled trials. It followed 310 adults with relapsing MS who had been on the treatment for at least a year. The main goal was to see how often patients had symptom flare-ups (relapses) and to check the treatment's safety and how well people stuck with it in real life.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RELAPSING FORMS OF MULTIPLE SCLEROSIS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Novartis Investigative Site

    Santiago Compostela, A Coruna, 15706, Spain

  • Novartis Investigative Site

    Palma, Balearic Islands, 07120, Spain

  • Novartis Investigative Site

    L'Hospitalet de Llobregat, Barcelona, 08907, Spain

  • Novartis Investigative Site

    Santander, Cantabria, 39008, Spain

  • Novartis Investigative Site

    Albacete, Castille-La Mancha, 02006, Spain

  • Novartis Investigative Site

    Salt, Girona, 17190, Spain

  • Novartis Investigative Site

    Logroño, La Rioja, 26006, Spain

  • Novartis Investigative Site

    Fuenlabrada, Madrid, 28942, Spain

  • Novartis Investigative Site

    Majadahonda, Madrid, 28222, Spain

  • Novartis Investigative Site

    Pamplona, Navarre, 31008, Spain

  • Novartis Investigative Site

    Vigo, Pontevedra, 36212, Spain

  • Novartis Investigative Site

    Santa Cruz, Santa Cruz de Tenerife, 38009, Spain

  • Novartis Investigative Site

    Barakaldo, Vizcaya, 48903, Spain

  • Novartis Investigative Site

    Alicante, 03010, Spain

  • Novartis Investigative Site

    Barcelona, 08036, Spain

  • Novartis Investigative Site

    Burgos, 09006, Spain

  • Novartis Investigative Site

    Cáceres, 10004, Spain

  • Novartis Investigative Site

    Córdoba, 14004, Spain

  • Novartis Investigative Site

    Granada, 18016, Spain

  • Novartis Investigative Site

    León, 24080, Spain

  • Novartis Investigative Site

    Madrid, 28009, Spain

  • Novartis Investigative Site

    Madrid, 28034, Spain

  • Novartis Investigative Site

    Madrid, 28040, Spain

  • Novartis Investigative Site

    Madrid, 28041, Spain

  • Novartis Investigative Site

    Madrid, 28046, Spain

  • Novartis Investigative Site

    Málaga, 29010, Spain

  • Novartis Investigative Site

    Seville, 41009, Spain

  • Novartis Investigative Site

    Seville, 41013, Spain

  • Novartis Investigative Site

    Valencia, 46010, Spain

  • Novartis Investigative Site

    Valencia, 46026, Spain

  • Novartis Investigative Site

    Zaragoza, 50009, Spain

Conditions

Explore the condition pages connected to this study.

RELAPSING FORMS OF MULTIPLE SCLEROSIS